Literature DB >> 32234277

Predictive models for estimating cytotoxicity on the basis of chemical structures.

Hongmao Sun1, Yuhong Wang2, Dorian M Cheff2, Matthew D Hall2, Min Shen3.   

Abstract

Cytotoxicity is a critical property in determining the fate of a small molecule in the drug discovery pipeline. Cytotoxic compounds are identified and triaged in both target-based and cell-based phenotypic approaches due to their off-target toxicity or on-target and on-mechanism toxicity for oncology and neurodegenerative targets. It is critical that chemical-induced cytotoxicity be reliably predicted before drug candidates advance to the late stage of development, or more ideally, before compounds are synthesized. In this study, we assessed the cell-based cytotoxicity of nearly 10,000 compounds in NCATS annotated libraries against four 'normal' cell lines (HEK 293, NIH 3T3, CRL-7250 and HaCat) using CellTiter-Glo (CTG) technology and constructed highly predictive models to estimate cytotoxicity from chemical structures. There are 5,241 non-redundant compounds having unambiguous activities in the four different cell lines, among which 11.8% compounds exhibited cytotoxicity in two or more cell lines and are thus labelled cytotoxic. The support vector classification (SVC) models trained with 80% randomly selected molecules achieved the area under the receiver operating characteristic curve (AUC-ROC) of 0.88 on average for the remaining 20% compounds in the test sets in 10 repeating experiments. Application of under-sampling rebalancing method further improved the averaged AUC-ROC to 0.90. Analysis of structural features shared by cytotoxic compounds may offer medicinal chemists heuristic design ideas to eliminate undesirable cytotoxicity. The profiling of cytotoxicity of drug-like molecules with annotated primary mechanism of action (MOA) will inform on the roles played by different targets or pathways in cellular viability. The predictive models for cytotoxicity (accessible at https://tripod.nih.gov/web_adme/cytotox.html) provide the scientific community a fast yet reliable way to prioritize molecules with little or no cytotoxicity for downstream development.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytotoxicity; Mechanism of action; Multiple cell lines; Prediction; Support vector machine

Year:  2020        PMID: 32234277      PMCID: PMC7881917          DOI: 10.1016/j.bmc.2020.115422

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  21 in total

Review 1.  What is a support vector machine?

Authors:  William S Noble
Journal:  Nat Biotechnol       Date:  2006-12       Impact factor: 54.908

Review 2.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

Review 3.  Cell death assays for drug discovery.

Authors:  Oliver Kepp; Lorenzo Galluzzi; Marta Lipinski; Junying Yuan; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

4.  Modelling compound cytotoxicity using conformal prediction and PubChem HTS data.

Authors:  Fredrik Svensson; Ulf Norinder; Andreas Bender
Journal:  Toxicol Res (Camb)       Date:  2016-10-31       Impact factor: 3.524

5.  Phenotypic vs. target-based drug discovery for first-in-class medicines.

Authors:  D C Swinney
Journal:  Clin Pharmacol Ther       Date:  2013-04       Impact factor: 6.875

6.  Prediction of hERG Liability - Using SVM Classification, Bootstrapping and Jackknifing.

Authors:  Hongmao Sun; Ruili Huang; Menghang Xia; Sampada Shahane; Noel Southall; Yuhong Wang
Journal:  Mol Inform       Date:  2016-12-21       Impact factor: 3.353

Review 7.  Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.

Authors:  Nathan P Coussens; John C Braisted; Tyler Peryea; G Sitta Sittampalam; Anton Simeonov; Matthew D Hall
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

Review 8.  Phenotypic screens as a renewed approach for drug discovery.

Authors:  Wei Zheng; Natasha Thorne; John C McKew
Journal:  Drug Discov Today       Date:  2013-07-09       Impact factor: 7.851

Review 9.  Why is cancer drug discovery so difficult?

Authors:  Alexander Kamb; Susan Wee; Christoph Lengauer
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

10.  Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.

Authors:  Olivia W Lee; Shelley Austin; Madison Gamma; Dorian M Cheff; Tobie D Lee; Kelli M Wilson; Joseph Johnson; Jameson Travers; John C Braisted; Rajarshi Guha; Carleen Klumpp-Thomas; Min Shen; Matthew D Hall
Journal:  SLAS Discov       Date:  2019-09-09       Impact factor: 3.341

View more
  2 in total

Review 1.  Retro Drug Design: From Target Properties to Molecular Structures.

Authors:  Yuhong Wang; Sam Michael; Shyh-Ming Yang; Ruili Huang; Kennie Cruz-Gutierrez; Yaqing Zhang; Jinghua Zhao; Menghang Xia; Paul Shinn; Hongmao Sun
Journal:  J Chem Inf Model       Date:  2022-06-02       Impact factor: 6.162

2.  Image-Based Annotation of Chemogenomic Libraries for Phenotypic Screening.

Authors:  Amelie Tjaden; Apirat Chaikuad; Eric Kowarz; Rolf Marschalek; Stefan Knapp; Martin Schröder; Susanne Müller
Journal:  Molecules       Date:  2022-02-21       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.